Syndax Pharmaceuticals, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Syndax Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Syndax Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Syndax Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Syndax Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Syndax Pharmaceuticals, Inc.; Syndax Pharmaceuticals, Inc. - Key Therapeutics; Syndax Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Syndax Pharmaceuticals, Inc. - News; Syndax Pharmaceuticals, Inc. - Latest Updates; Syndax Pharmaceuticals, Inc. - Pipeline; Syndax Pharmaceuticals, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Syndax Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Syndax Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Syndax Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Syndax Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Syndax Pharmaceuticals, Inc. - Brief Syndax Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Syndax Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Syndax Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Syndax Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Syndax Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Syndax Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Syndax Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Syndax Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Syndax Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Syndax Pharmaceuticals, Inc.; Syndax Pharmaceuticals, Inc. - Key Therapeutics; Syndax Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Syndax Pharmaceuticals, Inc. - News; Syndax Pharmaceuticals, Inc. - Latest Updates; Syndax Pharmaceuticals, Inc. - Pipeline; Syndax Pharmaceuticals, Inc. - Discontinued/Dormant Projects
Syndax Pharmaceuticals, Inc. Snapshot
Syndax Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Syndax Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Syndax Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. – Pipeline Products Glance
Syndax Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. – Drug Profiles
Arimidex + Entinostat
Product Description
Mechanism of Action
R&D Progress
Aromasin + Entinostat
Product Description
Mechanism of Action
R&D Progress
Clolar + Entinostat
Product Description
Mechanism of Action
R&D Progress
Femara + Entinostat
Product Description
Mechanism of Action
R&D Progress
Nexavar + Entinostat
Product Description
Mechanism of Action
R&D Progress
Proleukin + Entinostat
Product Description
Mechanism of Action
R&D Progress
Sargramostim + Entinostat
Product Description
Mechanism of Action
R&D Progress
SNDX 275
Product Description
Mechanism of Action
R&D Progress
Tarceva + Entinostat
Product Description
Mechanism of Action
R&D Progress
Tykerb + Entinostat
Product Description
Mechanism of Action
R&D Progress
Vidaza + Entinostat
Product Description
Mechanism of Action
R&D Progress
Syndax Pharmaceuticals, Inc. – Pipeline Analysis
Syndax Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Syndax Pharmaceuticals, Inc. – Pipeline Products By Target
Syndax Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Syndax Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Syndax Pharmaceuticals, Inc. – Recent Pipeline Updates
Syndax Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Syndax Pharmaceuticals, Inc., Recent Developments
Syndax Pharmaceuticals, Inc.- Press Release
May 29, 2012: Syndax To Present Phase II Study Results Of Entinostat At ASCO Annual Meeting
Apr 30, 2012: Syndax Announces Publication Of Phase II Entinostat Trial Data In Journal Of Clinical Oncology
Apr 09, 2012: Syndax Initiates Phase I/II Study Of Entinostat In Combination With Lapatinib In HER2-Positive Metastatic Breast Cancer
Feb 08, 2012: Syndax Announces Entinostat Enhances Activity Of Cancer Immunotherapies In Renal And Prostate Cancer Models
Financial Deals Landscape
Syndax Pharmaceuticals, Inc., Deals Summary
Syndax Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Syndax Pharma Secures $6 Million In Venture Financing
Syndax Pharma Raises $9 Million In Series A Financing
Syndax Pharma Secures $40 Million In Series A Financing
Partnerships
Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems
Licensing Agreements
Syndexa Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
Syndax Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Syndax Pharmaceuticals, Inc., Key Information
Syndax Pharmaceuticals, Inc., Key Facts
Syndax Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Syndax Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Syndax Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Phase III, 2012
Syndax Pharmaceuticals, Inc. – Phase II, 2012
Syndax Pharmaceuticals, Inc. – Phase I, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Syndax Pharmaceuticals, Inc. - Pipeline By Target, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Syndax Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Syndax Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Syndax Pharmaceuticals, Inc., Deals Summary
Syndax Pharma Secures $6 Million In Venture Financing
Syndax Pharma Raises $9 Million In Series A Financing
Syndax Pharma Secures $40 Million In Series A Financing
Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems
Syndexa Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
Syndax Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
LIST OF FIGURES
Syndax Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Syndax Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Syndax Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Syndax Pharmaceuticals, Inc. - Pipeline By Target, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Syndax Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012
Syndax Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Syndax Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Syndax Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. – Pipeline Products Glance
Syndax Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. – Drug Profiles
Arimidex + Entinostat
Product Description
Mechanism of Action
R&D Progress
Aromasin + Entinostat
Product Description
Mechanism of Action
R&D Progress
Clolar + Entinostat
Product Description
Mechanism of Action
R&D Progress
Femara + Entinostat
Product Description
Mechanism of Action
R&D Progress
Nexavar + Entinostat
Product Description
Mechanism of Action
R&D Progress
Proleukin + Entinostat
Product Description
Mechanism of Action
R&D Progress
Sargramostim + Entinostat
Product Description
Mechanism of Action
R&D Progress
SNDX 275
Product Description
Mechanism of Action
R&D Progress
Tarceva + Entinostat
Product Description
Mechanism of Action
R&D Progress
Tykerb + Entinostat
Product Description
Mechanism of Action
R&D Progress
Vidaza + Entinostat
Product Description
Mechanism of Action
R&D Progress
Syndax Pharmaceuticals, Inc. – Pipeline Analysis
Syndax Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Syndax Pharmaceuticals, Inc. – Pipeline Products By Target
Syndax Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Syndax Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Syndax Pharmaceuticals, Inc. – Recent Pipeline Updates
Syndax Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Syndax Pharmaceuticals, Inc., Recent Developments
Syndax Pharmaceuticals, Inc.- Press Release
May 29, 2012: Syndax To Present Phase II Study Results Of Entinostat At ASCO Annual Meeting
Apr 30, 2012: Syndax Announces Publication Of Phase II Entinostat Trial Data In Journal Of Clinical Oncology
Apr 09, 2012: Syndax Initiates Phase I/II Study Of Entinostat In Combination With Lapatinib In HER2-Positive Metastatic Breast Cancer
Feb 08, 2012: Syndax Announces Entinostat Enhances Activity Of Cancer Immunotherapies In Renal And Prostate Cancer Models
Financial Deals Landscape
Syndax Pharmaceuticals, Inc., Deals Summary
Syndax Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Syndax Pharma Secures $6 Million In Venture Financing
Syndax Pharma Raises $9 Million In Series A Financing
Syndax Pharma Secures $40 Million In Series A Financing
Partnerships
Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems
Licensing Agreements
Syndexa Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
Syndax Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Syndax Pharmaceuticals, Inc., Key Information
Syndax Pharmaceuticals, Inc., Key Facts
Syndax Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Syndax Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Syndax Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Phase III, 2012
Syndax Pharmaceuticals, Inc. – Phase II, 2012
Syndax Pharmaceuticals, Inc. – Phase I, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Syndax Pharmaceuticals, Inc. - Pipeline By Target, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Syndax Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Syndax Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Syndax Pharmaceuticals, Inc., Deals Summary
Syndax Pharma Secures $6 Million In Venture Financing
Syndax Pharma Raises $9 Million In Series A Financing
Syndax Pharma Secures $40 Million In Series A Financing
Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems
Syndexa Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
Syndax Pharma Enters Into Licensing Agreement With Bayer Schering Pharma
LIST OF FIGURES
Syndax Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Syndax Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Syndax Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Syndax Pharmaceuticals, Inc. - Pipeline By Target, 2012
Syndax Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Syndax Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012
